drugset / Trial / NCT00770692

A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

NCT00770692

Phase 3 Completed 369 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.

Timeline

Start
2008-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 1 mg Oral
Subject Eszopiclone Small molecule 2 mg Oral
Subject Eszopiclone Small molecule 3 mg Oral

Indications